cbdMD Inc shares fell by 19.17% in pre-market trading, crossing below the 5-day SMA. This decline occurs despite the broader market's positive performance, with the Nasdaq-100 up 0.57% and the S&P 500 up 0.38%. The stock's movement suggests sector rotation as investors may be reallocating their portfolios.
The drop in cbdMD's stock price is attributed to a lack of confirmed catalysts, as the company is set to host a conference call on December 19, 2025, to discuss its fourth quarter and fiscal year 2025 results. While this event may provide insights into the company's financial health, it does not constitute a confirmed catalyst that would drive immediate investor interest. Therefore, the stock's movement reflects broader market trends rather than specific company news.
Investors will be closely watching the upcoming conference call for any updates on cbdMD's business progress and financial status. However, the current price action indicates a shift in investor sentiment, potentially influenced by sector dynamics rather than company-specific developments.
Wall Street analysts forecast YCBD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for YCBD is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast YCBD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for YCBD is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.754
Low
2.00
Averages
2.00
High
2.00
Current: 0.754
Low
2.00
Averages
2.00
High
2.00
Maxim
Buy
downgrade
$3 -> $2
2025-08-20
Reason
Maxim
Price Target
$3 -> $2
AI Analysis
2025-08-20
downgrade
Buy
Reason
Maxim lowered the firm's price target on cbdMD to $2 from $3 and keeps a Buy rating on the shares. The firm cites the company's Q3 loss coming in wider than expected amid softness in demand and regulatory uncertainties, the analyst tells investors in a research note. Maxim adds that while the company has partnered with industry advocacy groups to engage legislators and prioritize compliance with product quality and labeling requirements, it expects regulatory headwinds to persist, limiting growth through 2026.
Maxim
Buy
downgrade
$16 -> $3
2025-05-22
Reason
Maxim
Price Target
$16 -> $3
2025-05-22
downgrade
Buy
Reason
About YCBD
cbdMD, Inc. is a consumer wellness company focused on the development, manufacturing, marketing, and sale of supplement brands powered by natural compounds. Its hemp-derived cannabinoids, include full-spectrum cannabidiol (CBD) formulations, hemp-derived Delta-9 THC products and a range of functional products designed to address key wellness needs, such as sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. It operates a multi-brand portfolio anchored by its flagship cbdMD line, which offers oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. Its Paw CBD pet-wellness brand provides tinctures, chews, and topicals for dogs and cats. Its ATRX platform offers non-cannabinoid functional ingredients such as functional mushrooms. Its Herbal Oasis (Oasis) brand is a premium hemp-derived THC-infused social seltzer that blends cannabinoids and nootropic mushrooms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
